



Stem Cell Transplantation for Sickle Cell Disease

An Educational Slide Set

American Society of Hematology 2021 Guidelines for Sickle Cell Disease Stem Cell Transplantation

Slide Set Authors:

Akshay Sharma, MBBS, St. Jude Children's Research Hospital, Memphis, TN and
John Tisdale, MD, Cellular and Molecular Therapeutics Branch, NHLBI, National Institutes of Health, Bethesda, MD



Clinical Guidelines

American Society of Hematology 2021 guidelines for sickle cell disease: stem cell transplantation

Julie Kanter, Robert I. Liem, Françoise Bernaudin, Javier Bolaños-Meade, Courtney D. Fitzhugh, Jane S. Hankins, M. Hassan Murad, Julie A. Panepinto, Damiano Rondelli, Shalini Shenoy, John Wagner, Mark C. Walters, Teonna Woolford, Joerg J. Meerpohl, and John Tisdale

Julie Kanter, Robert I. Liem, Françoise Bernaudin, Javier Bolaños-Meade, Courtney D. Fitzhugh, Jane S. Hankins, M. Hassan Murad, Julie A. Panepinto, Damiano Rondelli, Shalini Shenoy, John Wagner, Mark C. Walters, Teonna Woolford, Joerg J. Meerpohl, John Tisdale; American Society of Hematology 2021 guidelines for sickle cell disease: stem cell transplantation. *Blood Adv* 2021; 5 (18): 3668–3689.
doi: <https://doi.org/10.1182/bloodadvances.2021004394C>

Check for updates
CLINICAL GUIDELINES
blood advances

American Society of Hematology 2021 guidelines for sickle cell disease: stem cell transplantation

Julie Kanter,¹ Robert I. Liem,² Françoise Bernaudin,^{3,4} Javier Bolaños-Meade,⁵ Courtney D. Fitzhugh,⁶ Jane S. Hankins,⁷ M. Hassan Murad,⁸ Julie A. Panepinto,⁹ Damiano Rondelli,¹⁰ Shalini Shenoy,¹¹ John Wagner,¹² Mark C. Walters,¹³ Teonna Woolford,¹⁴ Joerg J. Meerpohl,^{15,16} and John Tisdale⁹

¹Department of Hematology/Oncology, University of Alabama Birmingham, Birmingham, AL; ²Division of Hematology, Oncology and Stem Cell Transplant, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL; ³French Referral Center for Sickle Cell Disease, Centre Hospitalier Intercommunal Creteil, Université Paris XII, Paris, France; ⁴Société Française de Greffe de Moelle et de Thérapie Cellulaire, Lille, France; ⁵Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD; ⁶Cellular and Molecular Therapeutics Branch, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD; ⁷Department of Hematology, St Jude Children's Research Hospital, Memphis, TN; ⁸Division of Preventive Medicine, Mayo Clinic, Rochester, MN; ⁹Medical College of Wisconsin/Children's Wisconsin, Pediatric Hematology, Milwaukee, WI; ¹⁰Division of Hematology/Oncology, University of Illinois at Chicago, Chicago, IL; ¹¹St Louis Children's Hospital, Washington University School of Medicine, St Louis, MO; ¹²Division of Blood and Marrow Transplantation, Department of Pediatrics, University of Minnesota, Minneapolis, MN; ¹³Benoff Children's Hospital, University of California San Francisco, Oakland, CA; ¹⁴Sickle Cell Reproductive Health Education Directive, Owings Mills, MD; ¹⁵Institute for Evidence in Medicine, Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany; and ¹⁶Cochrane Germany Foundation, Cochrane Germany, Freiburg, Germany

Background: Sickle cell disease (SCD) is a life-limiting inherited hemoglobinopathy that results in significant complications and affects quality of life. Hematopoietic stem cell transplantation (HSCT) is currently the only curative intervention for SCD; however, guidelines are needed to inform how to apply HSCT in clinical practice.

Objective: These evidence-based guidelines of the American Society of Hematology (ASH) are intended to support patients, clinicians, and health professionals in their decisions about HSCT for SCD.

Methods: The multidisciplinary guideline panel formed by ASH included 2 patient representatives and was balanced to minimize potential bias from conflicts of interest. The Mayo Evidence-Based Practice Research Program supported the guideline development process, including performing systematic evidence reviews (through 2019). The panel prioritized clinical questions and outcomes according to their importance for clinicians and patients. The panel used the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach, including GRADE Evidence-to-Decision Frameworks, to assess evidence and make recommendations, which were subject to public comment.

Results: The panel agreed on 8 recommendations to help patients and providers assess how individuals with SCD should consider the timing and type of HSCT.

Conclusions: The evidence review yielded no randomized controlled clinical trials for HSCT in SCD; therefore, all recommendations are based on very low certainty in the evidence. Key recommendations include considering HSCT for those with neurologic injury or recurrent acute chest syndrome at an early age and to improve nonmyeloablative regimens. Future research should include the development of a robust SCD registry to serve as a comparator for HSCT studies.

Summary of recommendations

Sickle cell disease (SCD) is the most common inherited clinically significant hemoglobinopathy in the United States. Individuals with SCD are affected by multiple disease-related complications that result in significant morbidities and early mortality. Hematopoietic stem cell transplantation (HSCT) is currently the only established curative intervention for SCD that can restore normal hematopoiesis. The American Society of Hematology (ASH) guideline panel addressed questions related to the use of HSCT for patients with SCD with neurologic injury, frequent pain, or acute chest syndrome (ACS). The panel also addressed questions related to the type of transplantation and donor used and age of the patient.

Submitted 28 January 2021; accepted 23 June 2021; final version published online 28 September 2021. DOI 10.1182/bloodadvances.2021004394. The full-text version of this article contains a data supplement. © 2021 by The American Society of Hematology

3668 KANTER et al. 28 SEPTEMBER 2021 • VOLUME 5, NUMBER 18

Downloaded from https://www.bloodadvances.org/ at National Institute of Health on September 27, 2021



ASH Clinical Practice Guidelines on SCD

1. Cardiopulmonary and Kidney Disease
2. Transfusion Support
3. Cerebrovascular Disease
4. Acute and Chronic Pain
5. **Stem Cell Transplantation**

How were these ASH guidelines developed?

PANEL FORMATION

Each guideline panel was formed following these key criteria:

- Balance of expertise (including disciplines beyond hematology, and patients)
- Close attention to minimization and management of conflicts of interest

CLINICAL QUESTIONS

10 clinically-relevant questions generated in PICO format (population, intervention, comparison, outcome)

Example: PICO question

“Should individuals with SCD and neurologic injury, including overt stroke, SCI, or abnormal TCD, undergo MSD transplantation??”

EVIDENCE SYNTHESIS

Evidence summary generated for each PICO question via systematic review of health effects plus:

- Resource use
- Feasibility
- Acceptability
- Equity
- Patient values and preferences

MAKING RECOMMENDATIONS

Recommendations made by guideline panel members based on evidence for all factors.

ASH guidelines are reviewed annually by expert work groups convened by ASH. Resources, such as this slide set, derived from guidelines that require updating are removed from the ASH website.



How to use these recommendations

	STRONG Recommendation ("The panel recommends...")	CONDITIONAL Recommendation ("The panel suggests...")
For patients	Most individuals would want the intervention.	A majority would want the intervention, but many would not.
For clinicians	Most individuals should receive the intervention.	Different choices will be appropriate for different patients, depending on their values and preferences. Use shared decision making .



Key terms: SCD related adverse events

- Stroke
 - acute neurologic injury of the brain, retina, or spinal cord that occurs as a result of ischemia or hemorrhage that last longer than 24 hours.
- Silent cerebral infarction (SCI)/silent stroke
 - a lesion visible by magnetic resonance imaging (MRI) images with no associated findings on neurologic exam.
 - can be correlated with neurocognitive and behavioral deficits.
- Acute chest syndrome (ACS)
 - a new radiodensity on chest radiograph together with fever and/or respiratory symptoms.



Key terms in stem cell transplantation

- Matched donor
 - A donor who is at least identical to the recipient at 8/8 or 10/10 human leucocyte antigen (HLA) loci.
 - A matched donor can be a sibling (matched sibling donor or MSD) or unrelated (matched unrelated donor or MUD).
- Graft versus host disease (GVHD)
 - An immunological complication of allogeneic hematopoietic stem cell transplantation (HSCT).
- Graft failure
 - A condition wherein the blood cell counts decrease following HSCT, or the proportion of the donor cells declines below a critical level in the peripheral blood and bone marrow.



Objectives

By the end of this session, you should be able to:

- Describe recommendations for HSCT in individuals with SCD in high-income settings.
- Describe recommendations for choice of:
 - conditioning regimen
 - alternative donor
 - graft source

... in individuals undergoing HSCT for SCD.




Background and Introduction



Comparing HSCT and Standard of Care for SCD

- HSCT is a potential 1-time curative therapy for SCD.
- HSCT for SCD is evolving - new conditioning regimens, alternative donors and methods of cell harvesting, and strategies for GVHD prevention.
- Success rates after HSCT are improving, **but** survival rates in children and adults with SCD receiving disease-modifying medication and supportive therapy are improving as well.
- Short- and long-term risks of HSCT must be considered in comparison to the currently approved therapies and new potentially curative therapies under development.

Risk of HSCT related complications with age





Case 1: Patient with neurological injury

A 4-year-old male with HbSS living in the United States, presents to your clinic for an annual visit. The child has recently had two abnormal TCD measurements (high MCA velocity). He is receiving hydroxyurea with good compliance since he was 2 years old. He has an HLA-matched 8-year-old sibling who has sickle cell trait. What is the next best step?

- A. Repeat TCD in 1 year.
- B. Continue hydroxyurea, but increase the dose.
- C. Start transfusion/apheresis to reduce sickle hemoglobin level.
- D. Discuss hematopoietic cell transplantation using the HLA-matched sibling as a donor.

HSCT for SCD patients with neurological injury: Recommendations

- HLA-matched related HSCT is suggested over standard of care (hydroxyurea/transfusion) in patients with SCD who have experienced an overt stroke or have an abnormal transcranial Doppler ultrasound (TCD) (conditional recommendation. very low certainty in the evidence).
- When considering transplantation for neurologic injury, children younger than age 16 years who receive matched sibling donor (MSD) HSCT have better outcomes than those older than age 16 years.




HSCT for SCD patients with neurological injury: Rationale

- Neurologic injury caused by overt stroke and SCI is a major complication of SCD.
- Up to 24% SCD patients could be affected by stroke.
- Chronic red cell transfusion (CRCT) and other supportive care therapy are useful in stroke prevention but not curative.
- Long-term CRCT is associated with risks such as alloimmunization and transfusional iron overload.
- Therefore, efforts to prevent primary or secondary stroke have focused on curative options such as HSCT.

HSCT vs CRCT for SCD patients with neurological injury

Figure 2. Time Course of Velocity and MRA Score Outcomes During the 3-Year Follow-up in Both Groups After Matching on Propensity Score Including Siblings Without SCA, Age, and Sex



TCD improved in those who received HSCT. New SCI developed in 3 patients who were receiving CRCT.



Case 2: Patient with severe symptoms

A 9-year-old female with HbS β^0 thalassemia has had 2 episodes of acute chest syndrome in the last 1 year. During the last episode, she required intensive care treatment and intubation. She has 3 siblings who do not have SCD. What is the next best step?



- A. Continue current management.
- B. Refer for gene therapy on a clinical trial.
- C. Start transfusion/apheresis to reduce sickle hemoglobin level.
- D. Perform HLA typing of the siblings to find a potential donor for HSCT.



HSCT for SCD patients with severe symptoms: Recommendations

- For patients with frequent pain or recurrent episodes of acute chest syndrome, consideration for transplantation should be given to patients who do not respond or have an inadequate response to standard of care, such as HU, new targeted therapies, or chronic transfusion therapies.
- For patients with SCD with an indication for HSCT **who lack an MSD**, suggest using transplants from alternative donors in the context of a clinical trial.
 - Alternative donor transplantation has the potential to improve or resolve disease manifestations in patients with severe SCD.
 - The risks related to transplantation complications should be balanced with benefits derived from successful transplantation.

HSCT using alternative donors





HSCT for SCD patients with severe symptoms: Rationale

- Patient-reported outcomes of pain intensity and pain impact improved post-HSCT in a subset of patients with only intermittent pain pre-HSCT.
- However, some patients (~40%) continue to experience pain post-HSCT. HSCT may not ameliorate chronic pain.
- ACS events no longer occur in patients in whom HSCT is successful.
- HSCT offers prospect of improved quality of life and prolonged survival when standard of care therapy is not successful.

Considerations for an allogeneic HSCT (conditional recommendations)

- Suggest using either total-body irradiation (TBI) #400 cGy or chemotherapy-based conditioning regimens for allo HSCT.
- In children with MSD, use myeloablative conditioning regimens over reduced intensity conditioning (RIC).
- In adults with MSD, use non-myeloablative conditioning over RIC.
- In patients with an indication, perform transplant at an earlier age than at an older age (no recommendation if no MSD available, impact of age on outcome may be related to conditioning regimen used).
- If HLA-identical sibling cord blood unit is available with good cell dose and viability, it is preferred over bone marrow .



Considerations for an allogeneic HSCT: Conditioning regimen

- Chemotherapy-based myeloablative conditioning with busulfan and cyclophosphamide, with or without serotherapy with anti-thymocyte globulin, is the standard of care for **pediatric patients** with SCD undergoing MSD HSCT.
 - Incidence of graft failure is higher after RIC compared to myeloablative conditioning.
- Nonmyeloablative regimens based on low-dose TBI have been developed and seem highly effective in reversing the disease in **adult patients**.
 - Better tolerated than chemotherapy-based conditioning in adults.
 - Potential for fertility preservation.


Age at HSCT and relationship to conditioning intensity

- With **myeloablative conditioning**, EFS was highest in children younger than age 13 years and with an MSD.
- Patients older than age 13 years had not only lower EFS but also lower OS and higher chronic GVHD risk.
- With myeloablative conditioning, the risk of chronic GVHD is significantly higher in those older than 15 years of age.
- **Nonmyeloablative conditioning** demonstrated no chronic GVHD or associated transplantation-related mortality.
- However, EFS was only 87%, because 13% had graft rejection.

Risk score to predict outcomes after HSCT

Table 1. Risk score based on age at transplantation and type of donor (training cohort)

Age, y	Age score	Type of donor	Donor score	Total score	3-year probability/incidence % (95% CI)		
					EFS	Death without graft failure	Graft failure
≤12	0	HLA matched sibling	0	0	92 (89-94)	2 (0-4)	6 (4-9)
	0	HLA mismatched relative	2	2	62 (43-76)	8 (2-19)	30 (15-47)
	0	Matched unrelated donor	1	1	83 (69-91)	8 (2-18)	8 (2-18)
	0	Mismatched unrelated donor	2	2	68 (55-79)	5 (1-13)	27 (16-38)
≥13	1	HLA matched sibling	0	1	87 (81-92)	7 (4-11)	5 (2-10)
	1	HLA mismatched relative	2	3	52 (38-65)	10 (4-18)	38 (24-51)
	1	Matched unrelated donor	1	2	50 (34-64)	29 (17-43)	21 (10-33)
	1	Mismatched unrelated donor	2	3	49 (31-66)	23 (9-40)	28 (13-44)



Cord blood transplantation

- Neutrophil and platelet recovery delayed after cord blood transplantation compared to bone marrow transplantation, but no increase in infections or non engraftment.
- Trend towards lower acute and chronic GVHD with cord blood transplantation.
- No difference in overall survival or event free survival with cord blood transplantation.
- Hence cord blood transplantation preferred over bone marrow for SCD, provided sufficient cell dose is available.



Good Practice Statements

1. Ensure that potential patients have been seen and counseled by an SCD specialist in addition to a specialist in HSCT to review all available treatment options.
2. Providers should be adequately trained in the specialized care required by SCD patients, including supportive care, which differs from that of other disease states.
3. Disease and transplantation-related outcomes should be monitored in the short (<2 years) and long term (10-15 years) in all patients after HSCT.
4. Care providers should consider health literacy levels of patients and their families when advising on HSCT.
5. Care providers should consider the burdens of the HSCT procedure on patients and their families.
6. Shared decision making between patients and providers is suggested to establish optimal HSCT plans.



Acknowledgements

- ASH guideline panel members
- Mayo Clinic Evidence-Based Practice Research Program
- ASH support team: Starr Webb, Kendall Alexander, Robert Kunkle
- See more about the ASH SCD guidelines: <https://hematology.org/SCDguidelines>
- Disclosures: Akshay Sharma is the St. Jude Children's Research Hospital site principal investigator of clinical trials for genome editing of sickle cell disease sponsored by Vertex Pharmaceuticals/CRISPR Therapeutics (NCT03745287) and by Novartis (NCT04443907). The industry sponsors provide funding for the clinical trial, which includes salary support paid to Akshay Sharma's institution. Akshay Sharma has received consultant fee from Spotlight Therapeutics, Medexus Inc. and Vertex Pharmaceuticals. He has also received research funding from CRISPR Therapeutics and honoraria from Vindico Medical Education.